Beilstein J. Org. Chem. 2011, 7, 962–975.
3H, 2’’-H), 2.32 (s, 3H, 4’-H), 3.51 (s, 3H, OMe), 5.33 (q, J = [M + H]+ calcd for C24H29F9NO5SSi, 642.1387; found,
6.4 Hz, 1H, 1’’-H), 7.43–7.53, 7.85–7.87 (2 m, 3H, 2H, Ph), 642.1403.
10.10 (br s, 1H, NH) ppm; 13C NMR (125 MHz, CDCl3) δ
Typical procedure for the esterification of
−4.8, −4.7 (2 q, OTBS), 18.2 (q, C-4’), 21.9 (q, C-2’’), 25.9,
4-pyridones with 3,3,3-trifluoro-2-methoxy-2-
phenylpropanoic acid (Procedure 4)
27.2 (2, q, OTBS), 60.9 (q, OMe), 65.6 (d, C-1’’), 127.5, 128.8,
132.2, 134.2, 139.6, 141.9 (3 d, 3 s, Ph, C-1’, C-2’), 165.0 (s,
C-1), 200.2 (s, C-3’) ppm; IR (ATR) : 3315 (NH), 2955–2855
(=CH, C-H), 1720–1515 (C=O, C=C) cm−1; HRMS–ESI (m/z):
[M + H]+ calcd for C20H31NNaO4Si, 400.1915; found,
400.1930.
Pyridone 22 (22 mg, 0.06 mmol) was dissolved in anhydrous
CH2Cl2 (0.3 mL) and anhydrous pyridine (0.3 mL), and (S)-
3,3,3-trifluoro-2-methoxy-2-phenylpropanoic acid (17 µL,
0.09 mmol) added. The mixture was stirred under an atmos-
phere of argon at r.t. for 16 h. After complete consumption of
the starting material (TLC), the mixture was diluted with
CH2Cl2 (10 mL) and the organic layer was successively washed
with sat. NaHCO3 solution, 1 M HCl and H2O (10 mL each).
The organic layer was dried with Na2SO4, filtered and the
solvent was removed under reduced pressure to afford 49
(25 mg, 68%) as a colorless oil.
Typical procedure for the cyclization of
β-alkoxy-β-ketoenamides to 4-hydrox-
ypyridines and subsequent nonaflation
(Procedure 3)
Enamide 64 (40 mg, 0.11 mmol) was dissolved in 1,2-
dichloroethane (2 mL) and placed in a sealable tube. Triethyl-
amine (48 µL, 0.32 mmol) and TMSOTf (58 µL, 0.32 mmol) (S,S)-2-tert-Butyl-6-[(tert-butyldimethylsiloxy)phenyl-
were added at r.t., and the resulting mixture was heated at 90 °C methyl]-3-methoxypyridin-4-yl 3,3,3-trifluoro-2-methoxy-2-
for 2 d. After complete consumption of the starting material phenylpropanoate (49): [α]D22 +14.0 (c 1.0, CHCl3); 1H NMR
(TLC), the reaction was quenched with sat. aq. NH4Cl solution (500 MHz, CDCl3) δ 0.01, 0.02, 0.96 (s, 3H, 3H, 9H, OTBS),
(2 mL). After extraction with dichloromethane (3 × 10 mL), the 1.35 (s, 9H, t-Bu), 3.49, 3.68 (2 s, 3H each, OMe), 5.80 (s, 1H,
combined organic layers were dried with Na2SO4 filtered and 1’-H), 7.17 (s, 1H, 5-H), 7.19–7.22, 7.27–7.31, 7.48–7.53,
the solvent was removed under reduced pressure. The crude 7.61–7.71 (4 m, 10H, Ph) ppm; 19F NMR (376 MHz, CDCl3) δ
product was purified by flash column chromatography (SiO2, −71.1 (s, CF3) ppm; IR (neat) : 2955–2930 (C-H), 1775
EtOAc/Methanol 10:1) to afford the respective pyridine deriva- (C=O), 1570–1450 (C=C), 1170–1105 (=C-H), 780–700 (C-F)
tive (36 mg, 94%) as a brown liquid.
cm−1; HRMS–ESI (m/z): [M + H]+ calcd for C33H43F3NO5Si,
618.2857; found, 618.2896.
The pyridine derivative (33 mg, 0.09 mmol) was dissolved in
THF (3 mL) and NaH (6.6 mg, 0.28 mmol) added under an
argon atmosphere. Nonafluorobutanesulfonyl fluoride (50 µL,
0.28 mmol) was added dropwise at room temperature. The mix-
ture was stirred at the same temperature for 12 h and quenched
by the slow addition of water. The resulting product was
extracted with diethyl ether (3 × 10 mL), dried with Na2SO4,
filtered and concentrated to dryness. The residue was purified
by column chromatography on silica gel (eluent: 2–5% EtOAc
in hexane) to afford 70 (39 mg, 67%) as a colorless oil.
Supporting Information
Supporting Information File 1
Experimental procedures and characterization data.
Supporting Information File 2
1H NMR and 13C NMR spectra of synthesized compounds.
(S)-2-[1-(tert-Butyldimethylsiloxy)ethyl]-3-methoxy-6-phe-
nyl-pyridin-4-yl nonaflate (70): [α]D22 −21.2 (c 0.3, CHCl3);
1H NMR (500 MHz, CDCl3) δ 0.00, 0.05, 0.87 (3 s, 3H, 3H,
9H, OTBS), 1.60 (d, J = 6.6 Hz, 3H, 2’-H), 3.95 (s, 3H, OMe), Acknowledgements
5.30 (q, J = 6.6 Hz, 1H, 1’-H), 7.42–7.48 (m, 3H, Ph), 7.51 (s, Generous support of this work by the Deutsche Forschungsge-
1H, 5-H), 7.97–7.98 (m, 2H, Ph) ppm; 13C NMR (125 MHz, meinschaft (SFB 765), the Studienstiftung des Deutschen
CDCl3) δ −4.6, −4.4 (2 q, OTBS), 18.3 (q, C-2’), 25.9, 30.3 (2, Volkes (PhD fellowship to CE) and the Bayer Schering Pharma
s, OTBS), 62.6 (q, OMe), 68.8 (d, C-1’), 112.3, 126.9, 128.8, AG is most gratefully acknowledged. We thank Dr. R. Zimmer
129.5, 137.7, 144.4, 150.1, 153.7, 160.0 (4 d, 5 s, Ph, C-2, C-3, for help during the preparation of the manuscript.
C-4, C-5, C-6) ppm; IR (ATR) : 3310 (NH), 3010–2835
(=CH, C-H), 1685–1510 (C=O, C=C) cm−1; HRMS–ESI (m/z):
973